SINGAPORE, April 11, 2025 — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR), also known as “CUPR” or “the Company,” a biomedical and biotechnology firm focused on creating and selling products for chronic wound management and cosmeceuticals for the health and beauty industry, announced today that it has completed its previously announced initial public offering of 3,000,000 Class A Ordinary Shares (“the Offering”) to the public at a price of $4.00 per share (“the Offering Price”), resulting in total gross proceeds of $12.0 million before deducting underwriting discounts and offering expenses.

The Company plans to use the net proceeds from the Offering to expand into new markets, conduct R&D to broaden its product line, boost brand recognition, invest in equipment and infrastructure, and for working capital and general corporate needs.

The shares began trading on the NASDAQ Stock Market LLC on April 10, 2025, under the ticker symbol “CUPR.”

R. F. Lafferty & Co., Inc. (“R. F. Lafferty”) served as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, and Harney Westwood & Riegels Singapore LLP acted as U.S., Singapore, and Cayman Islands legal counsel to the Company, respectively. Winston & Strawn LLP served as U.S. legal counsel to R. F. Lafferty for the Offering.

“We are pleased to close this Offering,” stated Cuprina CEO David Quek. “We believe our chronic wound care products are positioned to gain increasing market acceptance, primarily due to the growing global aging population and the associated increase in diabetes, obesity, cardiovascular diseases, and peripheral vascular diseases, all of which are linked to chronic wounds.”

“Our goal is to treat these wounds using sustainable, nature-derived raw materials that contain bioactives that have been widely demonstrated in clinical studies to produce better clinical results and lower treatment costs compared to most traditional treatment methods.”

The Offering is being made in accordance with the Company’s registration statement on Form F-1 (File No. 333-283643), as amended, which was previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on March 31, 2025. The Offering is being made solely through a prospectus, which is part of the registration statement. Copies of the final prospectus related to the Offering can be obtained, when available, from R. F. Lafferty & Co., Inc., 40 Wall Street, 27th Floor, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com. Additionally, a copy of the final prospectus, when available, relating to the Offering may be accessed via the SEC’s website at .

Before investing, you should consult the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy these securities. Furthermore, these securities will not be offered or sold in the United States without registration or an applicable exemption from registration, nor will there be any offer, solicitation, or sale of these securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company focused on developing and commercializing innovative products for managing chronic wounds and operating in the health and beauty sectors. Our biomedical research expertise enables us to identify and utilize materials from natural sources to create wound care products in the form of medical devices that meet international standards. For further details, please visit .

FORWARD-LOOKING STATEMENTS

Certain statements in this press release concerning future expectations, plans, and prospects, as well as any statements regarding matters that are not historical facts, may be considered “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the expected trading commencement and closing dates. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ significantly from those indicated by these forward-looking statements due to various important factors, including uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, as well as other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. Therefore, investors should not place undue reliance on any forward-looking statements in this press release. Any forward-looking statements in this press release are made only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email:

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email:

“`